Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial

    December 2021 in “ Cureus ”
    Flavio Cadegiani, Ricardo Ariel Zimerman, Daniel Fonseca … Andy Goren
    Studysummary This study found that proxalutamide significantly increased recovery rates, reduced mortality, and shortened hospital stays in hospitalized COVID-19 patients across different regions in Brazil.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on cureus.com →
    Discuss this study in the Community →

    Research cited in this study 18

    1. SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism Viruses · 2021
    2. Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide medRxiv (Cold Spring Harbor Laboratory) · 2021
    3. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial Frontiers in Medicine · 2021
    4. Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial medRxiv (Cold Spring Harbor Laboratory) · 2021
    5. Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – An Exploratory Analysis of the Proxa-Rescue AndroCoV Trial bioRxiv (Cold Spring Harbor Laboratory) · 2021
    6. The Antiandrogen Enzalutamide Downregulates TMPRSS2 and Reduces Cellular Entry of SARS-CoV-2 in Human Lung Cells Nature Communications · 2021
    7. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial Cureus · 2021
    8. Expression of Concern: Potential Risk for Developing Severe COVID-19 Disease Among Anabolic Steroid Users BMJ case reports · 2021
    9. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial Cureus · 2021
    10. Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men Journal of The European Academy of Dermatology and Venereology · 2021
    11. 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia Journal of The European Academy of Dermatology and Venereology · 2020
    12. Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19 Journal of the European Academy of Dermatology and Venereology · 2020
    13. Repurposing Existing Drugs for COVID-19: An Endocrinology Perspective BMC Endocrine Disorders · 2020
    14. Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients Journal of the European Academy of Dermatology and Venereology · 2020
    15. Male Balding as a Major Risk Factor for Severe COVID-19: A Possible Role for Targeting Androgens and Transmembrane Protease Serine 2 to Protect Vulnerable Individuals Journal of The American Academy of Dermatology · 2020
    16. Spironolactone: An Anti-Androgenic and Anti-Hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Frontiers in Medicine · 2020
    17. Male Balding Is a Major Risk Factor for Severe COVID-19 Journal of The American Academy of Dermatology · 2020
    18. Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign' Journal of The American Academy of Dermatology · 2020